A study to see the effect of unani drugs of Sufoof -e- Chobchini,Sharbat-e-Bazoori and Raughan-e-Baboona in patients of Niqras Muzmin(Chronic Gout).

An open-label Clinical Trial of Sufoof -e- Chobchini,Sharbat-e-Bazoori and Raughan-e-Baboona in cases of Niqras Muzmin (Chronic Gout). - CTNM

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015562

Enrollment

Registered

2018-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: M20-M25- Other joint disorders

Interventions

Intervention1: 1.Sufoof-e-chobchini,2.Sharbat-e- Bazoori,3.Raughan-e-baboona: 1.3gm with water two times a day morning and evening 42 days 2.20 ml two times a day morning and evening 42 days 3.5ml loc

Eligibility

Inclusion criteria

Inclusion criteria: Patients who meet the Score =8 for ACR 2015 criteria for diagnosis of gout. Specially those patients who agree to take this therapy.

Exclusion criteria

Exclusion criteria: Acute Gout Patients having complicated urate nephropathy Severe illnesses Pregnant and lactating women leukemia, Diabetes mellitus any genetic disorders Drug intolerance

Design outcomes

Primary

Measure	Time frame
Reduce serum Uric Acid level Reduce scoring in Gout Impact scale Relief in clinical presentationsTimepoint: 42 days	—

Secondary

Measure	Time frame
Reduce disabilities Improve quality of life Correction of deranged temperamentTimepoint: 6months	—

Countries

India

Contacts

Public ContactDr Shagufta Rahman

Regional Research institute of Unani medicine New Block AKTC AMU Aligarh

rrium_aligarh@rediffmail.com9368167574

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026